Douglas Francis Beach MD

Oncology•Philadelphia, PA

Hematologic Oncology

Associate Program Director of Internal Medicine Residency at Pennsylvania Hospital; Clinical Assistant Professor, University of Pennsylvania; Director of CREP/Breast and Ovarian Cancer Program at Pennsylvania Hospital

Join to View Full Profile

230 W Washington SqPhiladelphia, PA 19106
Phone+1 215-829-6088

Summary

Dr. Douglas Beach is an oncologist based in Philadelphia, PA, specialising in Hematologic Oncology. He completed his fellowship and residency in Hematology and Medical Oncology and Internal Medicine respectively at Cooper Medical School of Rowan University/Cooper University Hospital. His medical degree is from the Rutgers Robert Wood Johnson Medical School. Dr. Beach currently serves as an Assistant Professor of Medicine at the Hospital of the University of Pennsylvania. His areas of expertise include amyloidosis, non-hodgkin lymphoma, lung cancer, and hereditary breast/ovarian cancer. He has published significantly in his field and has been involved in multiple clinical trials, particularly focused on lymphomas.

Education & Training

Cooper Medical School of Rowan University/Cooper University HospitalFellowship, Hematology and Medical Oncology, 2009 - 2012
Cooper Medical School of Rowan University/Cooper University HospitalResidency, Internal Medicine, 2006 - 2009
Rutgers Robert Wood Johnson Medical SchoolClass of 2006

Certifications & Licensure

PA State Medical License 2011 - 2026
NJ State Medical License 2009 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies Start of enrollment: 2013 Jan 02
Terminated
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma Start of enrollment: 2015 Jun 01
Completed
Phase 2
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2015 Oct 21
TERMINATED
PHASE1
Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia Start of enrollment: 2015 Nov 19
TERMINATED
PHASE3
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma Start of enrollment: 2016 May 25
Terminated
Phase 2, Phase 3
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas Start of enrollment: 2018 Mar 16
RECRUITING
PHASE1
Join now to see all

Publications & Presentations

PubMed

55 citations
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
Anthony R. Mato, Lindsey E. Roeker, John N. Allan, John M. Pagel, Danielle M. Brander
American Journal of Hematology. 2018-11-01
5 citations
On the generalizability of prostate cancer studies: why race matters
Ohad Oren, M. Oren, Douglas F. Beach
Annals of Oncology. 2016-12-01
Superior vena cava syndrome as an initial presentation of low-grade follicular lymphoma.
Shakira Jeanene Grant, Simon Meykler, Doublas Beach
The Journal of Community and Supportive Oncology. 2014-11-01

Press Mentions

Beach-Rak Medicine LLC Debuts Its First App of the MD SeriesMay 28th, 2011